Longitudinal Investigation of Psychotherapy Outcomes (LIPO): Description of the Study Protocol

Leonardo Gonçalves *, Guillherme Kirsten Barbisan, Cinthia Danielle Araújo Vasconcelos Rebouças and Neusa Sica da Rocha

Post-Graduation Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Background: Despite extensive research in the field of psychotherapies, few studies have compared the primary psychotherapies of naturalistic design, which represents real-life situations.

Objective: The objectives of this study were to evaluate three modalities of evidence-based psychotherapy for clinical, psychosocial, and biological outcomes and to identify the mediators and confounders of this process. Our primary hypothesis is that all psychotherapies will improve clinical and psychosocial outcomes and will increase BDNF levels.

Methods: Design: longitudinal, naturalistic. Participants: One hundred twenty-six patients who underwent one of three evidence-based modalities of individual psychotherapy [psychodynamic psychotherapy (PDT), interpersonal psychotherapy (IPT), and cognitive–behavioral psychotherapy (CBT)] were included. Measure: Primary outcomes are divided into three domains of variables: clinical (general psychiatric symptoms), biological (serum BDNF levels), and psychosocial (resilience, quality of life, coping strategies, social support, and quality of life-adjusted years of life). Confounding/mediator variables included clinical (personality traits, type of psychotherapy, number of sessions, concomitant use of pharmacological treatment, history of previous psychotherapeutic treatment, medical and psychiatric comorbidities, and psychiatric diagnosis), psychosocial (psychosocial stressors, therapeutic alliance, and defense mechanism style), and other (religiosity) factors. Procedure: The follow-up period will be baseline and 6 months and 1 year after entering the study. The study will include 42 controls for biological variables only. Sample size calculation considered a significance level of 5% and a power of 80% to detect a difference of 0.22 with a standard deviation of 0.43, assuming losses of 20–30% of patients. The comparison between the modalities of psychotherapy will be by generalized estimating equations (GEE) model, the analysis of mediators by the Hayes method, and confounders by multivariate logistic regression.

Discussion: The findings of this study are intended to demonstrate the outcomes of evidence-based psychotherapies for clinical, psychosocial, and biological parameters and to understand the mediators and confounders of this process in a real-life setting.
INTRODUCTION

Psychotherapies are effective interventions for most mental disorders (1–4). A systematic review of 61 meta-analyses (852 clinical trials comprising a total of 137,126 participants) examined the effect of pharmacotherapy and psychotherapy for major psychiatric disorders. This review revealed that the effect sizes of psychotherapies tended to be larger \([0.58 \ (95\% \ CI, \ 0.40–0.76)]\) than those of pharmacotherapy \([0.40 \ (95\% \ CI, \ 0.28–0.52)]\). This investigation concluded that more support from public funding agencies is necessary for studies of psychotherapy (4).

Comparisons between different types of psychotherapy have long been a source of controversy (5), even with subsequent reproductions of meta-analyses (6, 7). This situation persists because of the dodo bird effect, i.e., that different techniques present similar effect size outcomes. The issue becomes more complex given that most studies do not have sufficient power to detect differences between psychotherapies. Furthermore, meta-analyses are composed of clinical trials with a considerable risk of bias (8).

Although there have been many randomized clinical trials (RCTs) evaluating the outcomes of psychotherapies, this is the first protocol of a study to evaluate main available evidence-based psychotherapies using a naturalistic longitudinal design and including patients referred from primary and secondary centers with complex and severe disorders. This design has the advantage of evaluating clinical outcomes in a real-world situation. Clinical trials, on the other hand, have the standardization of interventions, but can suffer from a lack of rigorous control related to the criteria for inclusion of patients; also, longitudinal studies have a level of evidence lower than that of randomized clinical trials and meta-analyses (9). To our knowledge, this is the first study with this design, because a Swedish naturalistic study by Werbert et al. compared three psychotherapies but used public health system records. Of the 1,498 patients, only 180 remained in the study, and the records were obtained mostly online. The study showed that there was no significant effect of the type of therapy, duration, or effect of the therapist, despite the limitations.

Reviewing the longitudinal studies in psychoanalytical psychotherapy published on PubMed, PsychInfo, and Embase databases within the last 5 years, we found seven studies (10–16), all of which were European. These studies were conducted mostly on patients with personality disorder, anxiety disorders, and depressive disorders. To the best of our knowledge, no published studies have followed up patients who underwent different kinds of psychotherapy.

The question of how to evaluate outcomes in psychotherapy is quite complicated and has been the subject of numerous studies (17). The most commonly used outcome measures in recent studies have included general psychiatric symptoms (10, 14), anxiety and depressive symptoms (13), coping and defense mechanisms (12), quality of life (16), and quality of life-adjusted years of life \([\text{Short-Form Six-Dimension (SF-6D)}]\) (10).

Psychotherapies can function by environmental epigenetic mechanisms, altering gene expression through methylation of the DNA of the serotonin transporter gene \((5\text{HTT})\) and altering imaging exams. However, this subject has been rarely studied (18). The search for biological markers of mental disorders has advanced in recent years, and this work has revealed neurotrophins. These neurotrophins, particularly brain-derived neurotrophic factor (BDNF), appear to be involved in the pathophysiological basis of many neurodegenerative and psychiatric disorders (19). BDNF is a neurotrophin distributed largely by the central nervous system that is involved in neuron growth, development, and plasticity (20, 21). It is associated with both mental disorders and physiological states such as sleep and alterations after interventions like electroconvulsive therapy (ECT) and antidepressants (19, 22).

Changes in BDNF have already been investigated in different psychotherapies (23) in clinical (24–26) and experimental contexts (27, 28), with contradictory results.

Patients with borderline personality disorder who underwent behavioral dialectical psychotherapy had a change of methylation of the BDNF gene at the end of the treatment that was associated with change scores in depression, hopelessness, and impulsivity (23). Patients with panic disorder who underwent cognitive–behavioral psychotherapy (CBT) and had a poor response had significantly lower serum BDNF than patients with a good response (29).

Despite the extensive literature of comparative studies of psychotherapies, there are still issues related to the effects of moderators and mediators in the psychotherapeutic process, especially considering a view of protective factors, biological factors, and outcomes that encompass factors of positive psychiatry such as quality of life and resilience. In addition, further studies are needed in naturalistic and severe patient contexts that assess psychotherapy in practice, seeking external validity.

AIMS

Our primary aim is to evaluate the outcomes associated with different forms of individual psychotherapy [psychodynamic psychotherapy (PDT), interpersonal psychotherapy (IPT), and CBT] in a public outpatient clinic for mental disorders. Our primary outcomes are divided into three domains of variables: clinical (general psychiatric symptoms), biological (serum BDNF levels), and psychosocial (resilience, quality of life, social support, and quality of life-adjusted years of life).

Our secondary aim is to evaluate potential confounders/mediators/moderators for the main outcomes: personality...
traits, type of psychotherapy, number of sessions, the therapist's duration of training, concomitant use of pharmacological treatment, history of previous psychotherapeutic treatment, medical and psychiatric comorbidities, psychiatric diagnosis, therapeutic alliance, and defense mechanisms.

Our main hypothesis is that all three modalities of therapy will produce reduction of symptoms in the clinical domain and improvement in the psychosocial domain. All psychotherapies will increase BDNF at 6 months of follow-up. As secondary hypotheses, the mechanisms of improvement will be mediated by the therapeutic alliance, motivational status, and defense mechanisms (for PDT). The confounders of this therapeutic improvement will be number of sessions, comorbidities, and medication use. The moderating factors will be gender, age, personality traits, religiosity, and defense mechanisms (for CBT).

METHODS

Design

The Longitudinal Investigation of Psychotherapy Outcome (LIPPO) study will compare three modalities of psychotherapy (PDT, CBT, and IPT) in a longitudinal course, in a naturalistic setting. The choice of the three modalities of psychotherapy is evidence-based and listed in guidelines for indication of first-line treatment for depression (30, 31).

The evaluations will take place in three moments: in the baseline (until the fourth session of psychotherapy) and 6 and 12 months after entering the study. The invited participants will be the patients who are undergoing any psychotherapy in the outpatient clinic of the Hospital de Clínicas of Porto Alegre (HCPA).

Participants

All patients included at the HCPA psychotherapy clinic will be evaluated by a fourth-year psychiatry resident with training in psychotherapy. Patients will be referred from the outpatient clinic of clinical psychiatry, pain medicine, or preoperative bariatric surgery. Each patient who agrees will undergo up to five evaluation interviews and engage in discussions with a supervisor. They will be next referred, based on clinical judgment, to the most suitable modality of psychotherapy. The clinic offers three methods of individual psychotherapy: PDP, IPT, and CBT.

The psychotherapy modality will be indicated by general criteria (17), considering the following characteristics: previous favorable experience with some kind of psychotherapy, psychological-mindedness, presence of personality disorder or traits, number of diagnoses of psychiatric disorders, and relief of symptoms. When diagnosed with personality disorder associated with one or more major psychiatric disorders and psychological-mindedness, PDT will be indicated. When there are up to two major psychiatric diagnoses without personality disorder, it will be directed to CBT as well as in the exclusive quest for symptom relief. When the focus of the problem is exclusively up to two of the following: 1) dispute, 2) roles dispute, 3) role transition, or 4) interpersonal deficits and no personality disorder, IPT will be indicated.

Psychotherapeutic care will be provided by psychiatry residents in their second, third, and fourth years of residency in psychiatry under weekly supervision of dialogued interviews. The residents have weekly theoretical seminars related to each of the psychotherapeutic techniques offered throughout the period of residence. They also engage in weekly clinical seminars in which patients are interviewed by teachers to prompt discussions about the clinical aspects related to cases. When there is doubt about patient management, the patient is interviewed by the supervisor.

Measures

Outcomes and Instruments

For the purposes of this study, outcomes were divided into clinical, psychosocial, and biological domains to make the study as comprehensive as possible in understanding the complex processes of change that may occur in psychotherapies (Table 1). The clinical domain refers to the more traditional measures of symptoms used to mediate the effectiveness of psychotherapy.

### TABLE 1 | Assessments according to time of psychotherapy.

| Outcomes/confusion factors | Baseline | 6 months | 12 months |
|----------------------------|----------|----------|-----------|
| **1. Primary outcomes**    |          |          |           |
| 1.1 Clinical domain        |          |          |           |
| Depression symptoms (BDI)  | X        | X        | X         |
| Anxiety symptoms (BAI)     | X        | X        | X         |
| Psychiatric symptoms (SCL-90-R) | X | X | X |
| **1.2 Biological domain**  |          |          |           |
| Serum BDNF                 | X        |          | X         |
| **1.3 Psychosocial domain**|          |          |           |
| Quality of life (WHOQOL-BREF) | X | X | X |
| Resilience (CDRISC)        | X        | X        | X         |
| Social support (MOS)       | X        | X        | X         |
| Quality of life-adjusted years (SF-6D) | X | X | X |
| **2. Confusion/mediator factors** | | | |
| 2.1 Clinical domain        |          |          |           |
| Diagnosis (review of medical records) | X | | X |
| Psychodynamic Diagnosis (OPD-II) | X | | |
| **Comorbidities**          |          |          |           |
| Pharmacological treatment  | X        | X        | X         |
| Personality traits (PID-V) | X        | X        | X         |
| Number of sessions         | X        | X        | X         |
| Type of psychotherapy      | X        |          |           |
| **2.2 Psychosocial domain**|          |          |           |
| Psychosocial stressors (LEQ) | X | X | X |
| Therapeutic alliance (CALPAS) | X | X | X |
| Motivational status (URICA) | X | X | X |
| Defense mechanism style (DSQ-40) | X | X | X |
| **2.3 Others**             |          |          |           |
| Religiosity (DUREL/WHOQOL-SRPB BREF) | X | X | X |

BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; SCL-90-R, Symptom Checklist-90—Revised; BDNF, brain-derived neurotrophic factor; WHOQOL-BREF, World Health Organization Quality of Life BREF; CD-RISC-25, Connor–Davidson-25 Scale of Resilience; MOS, the Medical Outcomes Study; SF-6D, Short-Form Six-Dimension; OPD-II, Operationalized Psychodynamic Diagnosis; PID-V, the Personality Inventory for DSM-5; LEQ, the Life Events Questionnaire; CALPAS, California Psychotherapy Alliance Scale; URICA, The University of Rhode Island Change Assessment, DSQ-40, The Defense Style Questionnaire; DUREL, Duke University Religion Index; WHOQOL-SRPB-BREF, World Health Organization Quality of Life BREF — Spirituality.
(13, 14). The psychosocial domain relates to the most current tendency of understanding the impact of an intervention on a patient's functionality, general well-being, and quality of life (10). The biological domain will evaluate the impact of psychotherapy on BDNF (23, 32).

**Domain of Clinical Variables**

**Psychiatry Symptomatology—General Symptomatology** The Symptom Checklist-90-Revised (SCL-90-R) is a self-administered scale consisting of 90 items distributed over nine dimensions: somatization, depression, interpersonal, obsessive–compulsive sensitivity, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. The scales of answers range from 0 (not at all) to 4 (an extreme degree of injury). Over the 6 months after discharge from the clinical follow-up, only paranoid ideation and the psychosis domains are considered. This situation results in a total of 16 items. The next follow-ups are conducted face to face, which allows for the application of the entire checklist (33).

**Symptoms of Anxiety and Depression: Beck Depression Inventory and Beck Anxiety Inventory (BAI)** These self-report rating inventories, developed by Beck, aim to measure symptoms of depression and suicidal ideation [Beck Depression Inventory (BDI)] and anxiety [Beck Anxiety Inventory [BAI]] (34).

**Domain of Biological Variables**

**Serum Levels of BDNF**

**Blood Collection** Serum samples will be obtained by venipuncture, and the blood will be immediately centrifuged at 3,000 × g for 5 min. The samples will be stored at ~80°C until biochemical analysis.

The levels of neurotrophins (BDNF) will be measured using a sandwich ELISA kit (enzyme-linked immunosorbent assay; Elabscience®, Houston, TX, USA), according to the manufacturer's instructions, with techniques standardized by our group. The total quantity of proteins was measured according to the Lowry method.

**Storage and Analysis of Blood Samples** The laboratory tests will be conducted at the Molecular Psychiatry Laboratory. The samples were stored in an appropriate laboratory managed by Gupo de Pesquisa e Pós-Graduação do Hospital de Clínicas de Porto Alegre (GPPG–HCPA).

**Domain of Psychosocial Variables**

**Quality of Life** The World Health Organization Quality of Life—BREF (WHOQOL-BREF) is an abbreviated quality of life instrument developed by the World Health Organization. It consists of 26 items that are answered in response scales ranging from 1 to 5, and it is based on a four-domain structure (physical, psychological, social, and environmental) (35, 36).

**Resilience** The Connor–Davidson Resilience Scale (CD-RISC) is a widely used self-report consisting of a 25-item questionnaire for evaluating individual resilience. It is divided into four domains: tenacity, adaptability–tolerance, reliance on support from the outside, and intuition (37, 38).

**Social Support** The Medical Outcomes Study (MOS) Social Support Survey consists of 20 self-reported items (39).

**Quality of Life-Adjusted Years** The SF-6D was adapted to Brazilian Portuguese–Brazil (version 2002). This self-administered instrument produces a unique score, which ranges from 0 to 1. The score represents the strength of an individual's preference for a given health condition; 0 corresponds to the worst health status and 1 corresponds to the best health status (40).

**Confusion/Mediator/Moderator Factors**

The mediating factors will be therapeutic alliance, motivation, and defense mechanisms (for PDT only). The moderating factors will be gender, age, religiosity, stressors, social support, personality traits, and defense mechanisms (for CBT and IPT). The confounding factors considered will be diagnosis, medication use, number of sessions, and comorbidities.

**Domain of Clinical Variables**

**Diagnosis** The psychodynamic diagnosis was based on Operationalized Psychodynamic Diagnosis (OPD II), a multiaxial diagnostic system for psychodynamically oriented therapists and psychiatrists (41, 42).

**Personality Assessment** The Personality Inventory for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) (PID-5)—Adult (43). A set of 25 core elements of personality description that combine in five broad domains of maladaptive personality variation: negative affect, detachment, antagonism, disinhibition, and psychoticism (43).

**Domain of Psychosocial Variables**

**Psychosocial Stressors** The Life Events Questionnaire (LEQ) evaluates the occurrence of 14 stressful life events over the last 12 months and the impact of these events on the subject’s life. The LEQ also focuses on the stressors’ association with the onset of current psychiatric problems (44).

**Therapeutic Alliance** The California Psychotherapy Alliance Scale (CALPAS) is a 24-item self-applicable questionnaire (45).

**Defense Mechanism Style** The Defense Style Questionnaire (DSQ-40) is a 40-item self-applicable questionnaire that aims to identify derivatives of defense mechanisms (46).

**Motivational Status** The University of Rhode Island Change Assessment (URICA) assesses motivation for change by providing scores on four stages of change: precontemplation, contemplation, action, and maintenance (47).

**Domain of Other Variables**

**Religiosity** The Duke University Religion Index (DUREL) is a five-item measure of religious involvement. It was developed for use in large cross-sectional and longitudinal observational studies (48, 49).
(WHOQOL-SRPB BREF) is an abbreviated version of the WHOQOL-SRPB that assesses spiritual, religious, and personal beliefs within quality of life; respondents choose the most suitable item from each of the eight SRPB facets and the one spirituality item (meaning of life) located in the psychological domain of the WHOQOL-BREF (36, 50).

Sample Size Estimation
Our sample size calculation relied on the study of Schaf (51) using BDNF serum levels before and after psychotherapy as outcomes. We arrived at a number of 42 subjects for each psychotherapy and control group, considering a significance level of 5% and a power of 80% difference to be detected 0.22 with a standard deviation of 0.43 and losses of 20–30%. We estimated a total sample size of 126 patients and 42 blood donor healthy controls for biological variable (as comparative of BDNF samples). The inclusion criteria will include having started psychotherapy within 1 month, an age above 18 years, and a BDI score greater than 15. The exclusion criteria will include psychotic disorders, current use of psychoactive substances, cognitive deficits, and dementias.

The study will include a subsample of healthy controls for control of blood samples that were recruited from the HCPA blood bank. The exclusion criteria for the control group included conditions (current or past) that precluded participation in the study (e.g., psychiatric disorders and/or psychiatric treatments), immune disorders, use of immunosuppressants, anti-inflammatory drugs used for fewer than 3 weeks, smoking, abuse and/or drug addiction, and infectious diseases for fewer than 3 weeks.

Statistical Analysis
Shapiro–Wilk test will be used to determine normality. For parametric distributions, dependent or independent $t$ tests will be performed. To determine differences between categorical variables, the chi-squared test will be used. For nonparametric distributions, we will use the Wilcoxon test and Mann–Whitney $U$ test to compare nonrelated and related means, respectively. A generalized estimating equations (GEE) model will be used to investigate multivariate repeated measurements. The Hayes method will be used to analyze the mediators (52), and the multivariate regression will be used to analyze the confounders. Post hoc analyses will be performed using the Bonferroni test.

The data will be expressed as mean ± standard deviation (SD), and a $p$ value less than or equal to 0.05 will be considered to be statistically significant (two-tailed). The statistical analyses will be performed using the SPSS version 20.0 software package (IBM®, New York, USA).

Procedure
The study will be disseminated through the presentation of its protocol in meetings with the outpatient services of the HCPA that refer patients to the psychiatry service, such as the internal medicine, pain, and bariatric surgery outpatient clinic.

The researchers will not participate in the indication of treatment of patients or in their assistance. Patients will be sought weekly in the HCPA outpatient medical records and through contact with resident physicians screening new patients. Those who fall into the eligibility criteria will be contacted by phone by the research assistant and invited to participate. It will be explained that refusal to participate will not entail any loss to the treatment. If they agree to participate, they will be asked to attend the HCPA Clinical Research Center (CPC-HCPA), where they will receive the informed consent form, sociodemographic interview, OPD interview, BDNF blood collection, and protocol with self-administered questionnaires. The consent form and OPD will be applied by the researchers. Patients will be contacted by telephone for the follow-up of 6 and 12 months (Figure 1).

Location
This study will be conducted in the city of Porto Alegre in the state of Rio Grande do Sul in far-southern Brazil. This region has Portuguese, Italian, German, and African influence. It has a population of 1.4 million, and it is the 10th most populous city in Brazil. Its ethnic distribution is as follows: White (79.2%), Black (10.2%), and Pardo (multiracial) people (10.6%). Its religious distribution is as follows: Catholic (83%), Protestant (9%), and others and atheists (8%). Brazil is a country with a high level of religiosity, and it is common for people to associate improvements in their health as being due to their faith (53). The role of religiosity in psychotherapies has not yet been clarified. According to the World Crime Index, Brazil ranks 9th, with Porto Alegre and São Paulo in the 11th and 14th place, respectively; so many patients experience a high level of urban violence and, consequently, severe life stressors related to this.

DISCUSSION
The only naturalistic longitudinal study that we found concluded that there was no significant difference in outcomes between therapies, as well as among therapists. However, these results need to be viewed with caution given some limitations related to loss, incomplete data, and the lack of long-term follow-up. Our study used direct contact with patients, which increased the number of variables and collection of BDNF as a possible biomarker in response to psychotherapy intervention.

Historically, studies in psychotherapy have been difficult to perform because they involve multiple factors and variables that are interrelated. Many variables may act as only associated factors, and others (e.g., mediators, predictors and even as confounders) may have varying effect sizes. We had difficulty defining some variables as mediators or confounders because the mechanism by which psychotherapies work is a matter of debate (54). We are interested in determining what is common to all psychotherapies. Therefore, we relied on published studies (16) and clinical experience.

Regarding the biological factors, studies of biomarkers such as BDNF may provide insights into the possible mechanisms of illness and recovery from serious disorders such as depression, bipolar disorder, and schizophrenia.
A few studies have evaluated this neutrophilin in the context of psychotherapies (29, 55). However, the mechanisms by which long-term psychotherapies produce changes in neuronal circuits and biomarkers, such as BDNF, have not yet been determined. In addition, most existing studies are characterized by follow-up durations of fewer than 12 weeks. As a result, they may be unable to detect changes that occur more slowly than those observed in BDNF with psychotropic drugs (56).

Considering the severity profile of patients referred to a tertiary medical center and the level of experience of resident physicians, the magnitude of improvement is lower than in other more favorable clinical settings. This improvement should be more pronounced in the 12-month follow-up considering the long-term effects of psychotherapies. The level of therapeutic alliance may possibly mediate this improvement. We believe that it will also reflect patients' psychosocial factors and increase BDNF.

Limitations of this study include the heterogeneity of the training and experience of the resident psychiatrists and the absence of evaluation from their point of view in the psychotherapeutic process. As a study is naturalistic, there is no way to control all differences between groups. Also, psychotherapy studies often have large amounts of losses (16). To control this bias, we will compare the clinical and demographic characteristics of the lost sample with those that continue in relation to the baseline. As for the multiplicity of diagnoses that may be found, to homogenize the sample, we will consider for inclusion the BDI value >15.

Studies such as this one seek to contribute to the foundations of public health policies and investments for the treatment of patients with severe mental illnesses who are at risk of hospitalization and suicide. These types of investigations also seek to promote mental health, rehabilitation, and social reintegration. Understanding the mediating and biological mechanisms of the psychotherapeutic process can help to optimize these interventions and facilitate their indication according to the psychopathological profile and the severity of the patients.

**ETHICS STATEMENT**

This project was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre (GPPG–HCPA no 97-2015), and it is recognized by the CONEP Conselho Nacional de Ética em Pesquisa—National Council of Ethics in Research.
AUTHOR CONTRIBUTIONS
LG and NR codeveloped the project. NR coordinated the project in HCPA. LG, GB, and CR were responsible for implementing, conducting, and collecting project data.

FUNDING
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil (CAPES)—Finance Code 001 and by Hospital de Clínicas de Porto Alegre Research Incentive Fund (FIEP).

REFERENCES
1. Correll CU, Carbon M. Efficacy of pharmacologic and psychotherapeutic interventions in psychiatry: to talk or to prescribe: is that the question? JAMA Psychiatry (2014) 71(6):624–6. doi: 10.1001/jamapsychiatry.2014.301
2. Cuijpers P. Combined pharmacotherapy and psychotherapy in the treatment of mild to moderate major depression? JAMA Psychiatry (2014) 71(7):747–8. doi: 10.1001/jamapsychiatry.2014.277
3. Dekker J, Van HL, Hendriksen M, Koelen J, Schoevers RA, Kool S, et al. What is the best sequential treatment strategy in the treatment of depression? Adding pharmacy treatment to psychotherapy or vice versa? Psychother Psychosom (2013) 82(2):89–98. doi: 10.1159/000341177
4. Huhn M, Tardy M, Spinelli LM, Kissling W, Forstl H, Pitschel-Walz G, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry (2014) 71(6):706–15. doi: 10.1001/jamapsychiatry.2014.112
5. Luborsky L, Singer B, Luborsky L. Comparative studies of psychotherapy. Is it true that “everyone has won and all must have prizes”? Arch Gen Psychiatry (1975) 32:995–1007. doi: 10.1001/archpsyc.1975.01760260059004
6. Luborsky L, Diguer L, Cacciola J, Barber JP, Moras K, Schmidt K, et al. Factors in outcomes of short-term dynamic psychotherapy for chronic vs. nonchronic major depression. J Psychother Pract Res (1996) 5(2):152–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22700274.
7. Wampoldt BE, Mondin GW, Moody M, Stich F, Benson K, Ahn HN. A meta-analysis of outcome studies comparing bona fide psychotherapies: empirically, “all must have prizes.” Psychol Bull (1997) 122(3):203–15. doi: 10.1037/0033-2909.122.3.203
8. Cuijpers P. Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies. Evil Based Ment Health (2016) 19(2):39–42. doi: 10.1116/eb-2016-102341
9. Atkins D, Best D, Briss PA, Eccles M, Fiksel J, Flottorp S, … GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ (2004) 328(7454):1490. DOI: 10.1136/bmj.328.7454.1490.
10. Berghout CC, Zevalkink J, Hakkak-Van Roijen L. A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. Int J Technol Assess Health Care (2010) 26(1):3–10. doi: 10.1017/S0266642309990791
11. D’Andrea W, Pole N. A naturalistic study of the relation of psychotherapy process to changes in symptoms, information processing, and physiological activity in complex trauma. Psychol Trauma (2012) 4(4):348–46. doi: 10.1037/a0025067
12. Kramer U, Despland JN, Michel L, Drapeau M, De Roten Y. Change in defense mechanisms and coping over the course of short-term dynamic psychotherapy for adjustment disorder. J Clin Psychol (2010) 66(12):1232–41. doi: 10.1002/jclp.20709
13. Lemma A, Target M, Fonagy P. The development of a brief psychodynamic intervention (dynamic interpersonal therapy) and its application to depression: a pilot study. Psychiatry (2011) 74(1):41–8. doi: 10.1521/psy.2011.74.1.41
14. Lo Coco G, Gullo S, Kivlighan DM. Examining patients’ and other group members’ agreement about their alliance to the group as a whole and changes in patient symptoms using response surface analysis. J Couns Psychol (2012) 59(2):197–207. doi: 10.1037/a0027560
15. Lurati C, Riva M, Resega R, Mantica C, Garassino MC, Sbrulati P, et al. A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer (2012) 20(3):475–81. doi: 10.1007/s00520-011-1096-x
16. Werbart A, Levin L, Andersson H, Sandell R. Everyday evidence: outcomes of psychotherapies in Swedish public health services. Psychothery (2013) 50(1):119–30. doi: 10.1037/a0031386
17. Fonagy P. Psychotherapy research: Do we know what works for whom? Br J Psychiatry (2010) 197(2):83–5. doi: 10.1192/bjp.bp.109.079657
18. Barsaglini A, Sartori G, Benetti S, Pettersson–Yeo W, Mechelli A. The effects of psychotherapy on brain function: a systematic and critical review. Prog Neurobiol (2014) 114:1–14. doi: 10.1016/j.pneurobio.2013.10.006
19. Nagahara AH, Tuszyński MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov (2011) 10(3):209–19. doi: 10.1038/nrd3366
20. Alleva E, Franza N. Psychiatric vulnerability: suggestions from animal models and role of neurotrophins. Neurosci Biobehav Rev (2009) 33(4):525–36. doi: 10.1016/j.neubiorev.2008.09.004
21. Cattaneo A, Cattane N, Begni V, Pariente CM, Riva MA. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. Transl Psychiatry (2016) 6(11):e958. doi: 10.1038/tp.2016.214
22. Nuernberg GL, Baeta FL, Fleck MP, Rocha NS. Outcomes of inpatients with severe mental illness: a naturalistic descriptive study. Rev Bras Psiquiatr (2016) 38(2):141–7. doi: 10.1590/1516-4446-2014.1643.
23. Perroud N, Salzmann A, Prada P, Nicostra R, Hoeppli ME, Furrer S, et al. Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry (2013) 3(1):e207–e208. doi: 10.1038/tp.2012.140
24. Cunha ABM, Frey BN, Andreazza AC, Goi JD, Rosa AR, Gonçalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett (2006) 389(3):215–9. doi: 10.1016/j.neulet.2005.12.085
25. Rosa AR, Frey BN, Andreazza AC, Ceresér KM, Cunha ABM, Quevedo J, et al. Increased serum glial cell line-derived neurotrophic factor immunocomtent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett (2006) 407(2):146–50. doi: 10.1016/j.neulet.2006.08.026
26. Rybakowski JK, Borkowska A, Czerski PM, Skińska M, Hauser J. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord (2003) 5(6):468–72. doi: 10.1046/j.1399-5618.2003.00071.x
27. Frey BN, Andreazza AC, Cereser KM, Martins MR, Valvassori SS, Rits GZ, et al. Effects of mood stabilizers on hippocampal BDNF levels in an animal model of mania. Life Sci (2006) 79(3):281–6. doi: 10.1016/j.lfs.2006.01.002
28. Walz JC, Frey BN, Andreazza AC, Cereser KM, Cailhaux AA, Valvassori SS, et al. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res (2008) 42(5):416–21. doi: 10.1016/j.jpsychires.2007.03.005
29. Kobayashi K, Shimizu E, Hashimoto K, Misumi N, Koike K, Okamura N, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients
with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. *Prog Neuropsychopharmacol Biol Psychiatry* (2005) 29(5):658–63. doi: 10.1016/j.pnpbp.2005.04.010

30. NICE. Depression in adults: recognition and management. Guidance and guidelines. NICE. (2009). Retrieved November 31, 2018, from https://www.nice.org.uk/guidance/cg90/chapter/update-information#update-information

31. Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. *Can J Psychiatry* (2016) 61(9):524–39. doi: 10.1177/0706743716659418

32. Koch JM, Hinze-Selch D, Stangele K, Göder R, Seeck-Hirschner M, et al. Changes in CREB Phosphorylation and BDNF plasma levels during psychotherapy of depression. *Psychother Psychosom* (2009) 78(3):187–92. doi: 10.1159/000209350

33. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. *Br J Psychiatry* (1976) 128(3):280–9. doi: 10.1192/bjp.128.3.280

34. Cunha J. Manual da versão em português das Escalas Beck. In: São Paulo: Casa do Psicólogo (2001). Retrieved from http://scholar.google.com/scholar?q=intitle:Manual+da+versão+em+português+das+Escalas+Beck#0

35. Fleck MPA, Louzada S, Chachamovich E, Vieira G, Santos L, Pinzon V. Aplicação da versão em português do instrumento abreviado de avaliação da qualidade de vida "WHOQOL-bref." *Rev Saúde Públ* (2000) 34(2):171–83. doi: 10.1590/S0034-8910200000002

36. Skevington SM, Gunson KS, O’Connell KA. Introducing the WHOQOL-SRPB BREF: developing a short-form instrument for assessing spiritual, religious and personal beliefs within quality of life. *Qual Life Res* (2013) 22(5):1073–83. doi: 10.1007/s11136-012-0237-0

37. Connor KM, Davidson JRT. Development of a new Resilience scale: the Connor–Davidson Resilience Scale among Brazilian adult patients. *Depress Anxiety* (2012) 34(3):129–38. doi: 10.1007/s10403-010-0600-1

38. Campolina AG, Bortoluzo AB, Ferraz MB, Gicconelli RM. o questionário SRPB BREF: desenvolvido uma escala curta para avaliar a qualidade de vida com base na psicopatologia. *Rev Bras Psiquiatr* (2011) 33(1):78–85. doi: 10.1590/S0104-39102011000100018

39. Chor D, Griep RH, Lopes CS, Faerstein E. [Social network and social support in the community]. *Rev Assoc Med Bras* (2014) 60(4):409–14. doi: 10.11606/s11136-012-0237-0

40. Campolina AG, Bortoluzo AB, Ferraz MB, Gicconelli RM. o questionário srpb bref: desenvolvido uma escala curta para avaliar a qualidade de vida com base na psicopatologia. *Rev Bras Psiquiatr* (2011) 33(1):78–85

41. Cierpka M, Grande T, Rudolf G, Von Der Tann M, Stasch M, Dahlbender RW, et al. The operationalized psychodynamic diagnostics system: clinical relevance, reliability and validity. *Psychopathology* (2007) 40(4):209–20. doi: 10.1159/000101363

42. Vicente CS, Oliveira RA, Silva F, Ferrajão P, Augusto S, Oliveira S, et al. Cross-cultural adaptation of the Operationalized Psychodynamic Diagnosis (OPD-2) in Portugal. *Trends Psychiatry Psychother* (2012) 34(3):129–38. doi: 10.1590/S2237-6089201200000004

43. Quilty LC, Ayearst L, Chmielewski M, Pollock BG, Bagby RM. The psychometric properties of the personality inventory for DSM-5 in an APA DSM-5 field trial sample. *Assessment* (2013) 20(3):362–9. doi: 10.1177/1073191113486183

44. Tennant C, Andrews G. A new scale to measure the cause of life events. *Aust NZ J Psychiatry* (1977) 11(3):163–7. doi: 10.1176/0048677/0919555

45. Gaston L. Reliability and criterion-related validity of the California Psychotherapy Alliance Scales—Patient Version. *Psychol Assess* (1991) 3:68–74. doi: 10.1037/1040-3590.3.1.68

46. Blaya C, Kipper L, Heldt E, Isolan L, Ceitlin LH, Bond M, et al. Brazilian–Portuguese version of the Defense Style Questionnaire (DSQ–40) for defense mechanisms measure: a preliminary study. *Rev Bras Psiquiatr* (2004) 26(4):255–8. doi: 10.1597/S1516-44642004006000010

47. McConnaughey EA, DiClemente CC, Prochaska JO, Velicer WE. Stages of change in psychotherapy: a follow-up report. *Psychother Theor Res Pract* (1989) 26(4):494–503. doi: 10.1037/h0085468

48. Koenig HG, Büssing A. The Duke University Religion Index (DUREL): a five-item measure for use in epidemiological studies. *Religions* (2010) 1(1):78–85. doi: 10.3390/re1010078

49. Luchetti G, Luchetti ALG, Peres MF, Leão FC, Moreira-Almeida A, Koenig HG. Validation of the Duke Religion Index: DUREL (Portuguese Version). *J Relig Health* (2012) 51(2):579–86. doi: 10.1007/s10943-010-9429-5

50. Malafaia G, de Lima Rodrigues AS, Talvani A. Ética Na Publicação De Pesquisas Sobre Leishmaniose Visceral Humana Em Periódicos Nacionais. *Rev Saude púb* (2011) 45(1):166–72. doi: 10.1590/S0034-89102011000100018

51. SchafDV. Estudo de fatores psicodinâmicos e neurobiológicos em psicoterapia psicodinâmica. Porto Alegre. Masters dissertation - Universidade Federal do Rio Grande do Sul. (2011).

52. Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. *Commun Monogr* (2009) 76(4):408–20. doi: 10.1080/03637775903310360

53. Mosquero BP, Da Rocha NS, Fleck MPDA. Intrinsic religiosity, resilience, quality of life, and suicide risk in depressed inpatients. *J Affect Disord* (2015) 179:128–33. doi: 10.1016/j.jad.2015.03.022

54. Kaidin AE. Understanding how and why psychotherapy leads to change. *Psychother Res* (2009) 19(4–5):418–28. doi: 10.1080/10503300802448899

55. Lester KJ, Hudson JL, Tropeano M, Creswell C, Collier DA, Farmer A, et al. Neurotrophic gene polymorphisms and response to psychological therapy. *Transl Psychiatry* (2012) 2(5):e108. doi: 10.1038(tp.2012.33

56. Viswede D, Taubner S, Buchheim A, Münte TF, Stach M, Cierpka M, et al. Tracking functional brain changes in patients with depression under psychodynamic psychotherapy using individualized stimuli. *PloS One* (2014) 9(10):e109037. doi: 10.1371/journal.pone.0109037

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Gonçalves, Barbisan, Reboças and da Rocha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.